File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Induction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinoma

TitleInduction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinoma
Authors
KeywordsInduction chemotherapy
Nasopharyngeal carcinoma
Cisplatin
Gemcitabine
Issue Date2006
Citation
Head and Neck, 2006, v. 28, n. 10, p. 880-887 How to Cite?
AbstractBackground. The purpose of this study was to evaluate the efficacy and toxicity of cisplatin plus gemcitabine as induction chemotherapy in advanced nasopharyngeal carcinoma (NPC). Methods. Thirty-seven patients with stage IV(A-B) NPC were treated with 3 cycles of cisplatin plus gemcitabine (cisplatin 80 mg/m 2 on day 1; gemcitabine 1250 mg/m 2 on days 1 and 8) 3-weekly as induction chemotherapy, followed by another 3 cycles of concurrent cisplatin (100 mg/m 2 on day 1) 3-weekly with accelerated radiotherapy (RT) at 70 Gy in 2-Gy fractions, 6 daily fractions per week. Results. The overall response rate to induction chemotherapy was > 90%, and side effects other than uncomplicated hematologic toxicities were uncommon. All patients completed RT, with 92% receiving ≥ 5 cycles of chemotherapy. At a median follow-up of 2.9 years, the 3-year overall survival (OS) and disease-free survival (DFS) rates were 76% and 63%, respectively. Conclusions. Cisplatin plus gemcitabine is a well-tolerated, effective, and convenient induction chemotherapy regimen and warrants further studies to confirm its benefit in advanced NPC. © 2006 Wiley Periodicals, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/213903
ISSN
2015 Impact Factor: 2.76
2015 SCImago Journal Rankings: 1.233

 

DC FieldValueLanguage
dc.contributor.authorYau, Tsz Kok-
dc.contributor.authorLee, Anne Wing Mui-
dc.contributor.authorWong, Dominique Hiu Ming-
dc.contributor.authorYeung, Rebecca Mei Wan-
dc.contributor.authorChan, Elian Wing Kin-
dc.contributor.authorNg, Wai Tong-
dc.contributor.authorTong, Macy-
dc.contributor.authorSoong, Inda Sung-
dc.date.accessioned2015-08-19T13:41:09Z-
dc.date.available2015-08-19T13:41:09Z-
dc.date.issued2006-
dc.identifier.citationHead and Neck, 2006, v. 28, n. 10, p. 880-887-
dc.identifier.issn1043-3074-
dc.identifier.urihttp://hdl.handle.net/10722/213903-
dc.description.abstractBackground. The purpose of this study was to evaluate the efficacy and toxicity of cisplatin plus gemcitabine as induction chemotherapy in advanced nasopharyngeal carcinoma (NPC). Methods. Thirty-seven patients with stage IV(A-B) NPC were treated with 3 cycles of cisplatin plus gemcitabine (cisplatin 80 mg/m 2 on day 1; gemcitabine 1250 mg/m 2 on days 1 and 8) 3-weekly as induction chemotherapy, followed by another 3 cycles of concurrent cisplatin (100 mg/m 2 on day 1) 3-weekly with accelerated radiotherapy (RT) at 70 Gy in 2-Gy fractions, 6 daily fractions per week. Results. The overall response rate to induction chemotherapy was > 90%, and side effects other than uncomplicated hematologic toxicities were uncommon. All patients completed RT, with 92% receiving ≥ 5 cycles of chemotherapy. At a median follow-up of 2.9 years, the 3-year overall survival (OS) and disease-free survival (DFS) rates were 76% and 63%, respectively. Conclusions. Cisplatin plus gemcitabine is a well-tolerated, effective, and convenient induction chemotherapy regimen and warrants further studies to confirm its benefit in advanced NPC. © 2006 Wiley Periodicals, Inc.-
dc.languageeng-
dc.relation.ispartofHead and Neck-
dc.subjectInduction chemotherapy-
dc.subjectNasopharyngeal carcinoma-
dc.subjectCisplatin-
dc.subjectGemcitabine-
dc.titleInduction chemotherapy with cisplatin and gemcitabine followed by accelerated radiotherapy and concurrent cisplatin in patients with stage IV(A-B) nasopharyngeal carcinoma-
dc.typeArticle-
dc.description.natureLink_to_subscribed_fulltext-
dc.identifier.doi10.1002/hed.20421-
dc.identifier.pmid16721741-
dc.identifier.scopuseid_2-s2.0-33749352303-
dc.identifier.hkuros266098-
dc.identifier.volume28-
dc.identifier.issue10-
dc.identifier.spage880-
dc.identifier.epage887-
dc.identifier.eissn1097-0347-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats